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Purpose: Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) binds to low-
density lipoprotein. The levels of Lp-PLA2 reflect the plaque burden, and are upregu-
lated in acute coronary syndrome (ACS). We investigated the diagnostic value of Lp-
PLA2 levels and found that it might be a potential biomarker for ACS. Materials and 
Methods: We classified 226 study participants into three groups: patients without 
significant stenosis (control group), patients with significant stenosis with stable angi-
na (SA group), and patients with ACS (ACS group). Results: Lp-PLA2 and high-
sensitivity C-reactive protein (hs-CRP) levels were significantly greater in the ACS 
group than in the SA group (p=0.044 and p=0.029, respectively). Multivariate logis-
tic regression analysis revealed that Lp-PLA2 levels are significantly associated with 
ACS (odds ratio=1.047, p=0.013). The addition of Lp-PLA2 to the ACS model sig-
nificantly increased the global χ2 value over traditional risk factors (28.14 to 35.602, 
p=0.006). The area under the receiver operating characteristic curve for Lp-PLA2 was 
0.624 (p=0.004). The addition of Lp-PLA2 level to serum hs-CRP concentration 
yielded an integrated discrimination improvement of 0.0368 (p=0.0093, standard er-
ror: 0.0142) and improved the ability to diagnose ACS. Conclusion: Lp-PLA2 levels 
are related to plaque stability and might be a diagnostic biomarker for ACS.
Key Words:   Lp-PLA2, acute coronary syndrome, biomarker, coronary atheroscle-
rotic plaque instability
INTRODUCTION
Cardiovascular disease is the major cause of death in most industrialized nations. 
Coronary heart disease (CHD) appears either as a stable disease, progressing slow-
ly over several years, or as an unstable disease, progressing rapidly and resulting in 
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review, with attention to clinical presentation, CAD risk fac-
tors, and medication, including lipid-lowering agents. Study 
participants were classified into three groups on the basis of 
their clinical presentation: 1) 53 cases with no significant 
stenotic lesions of the coronary arteries (control group); 2) 
57 cases of stable angina (SA group); and 3) 116 cases of 
ACS including 60 cases of unstable angina (UA) and 56 
cases of acute myocardial infarction (AMI) (ACS group). 
The age range was 36‒92 years (mean age 62.69±10.59 
years); 139 subjects were male and 87 were female. For all 
study groups, the exclusion criteria were malignant tumors, 
inflammatory disorders, severe liver disease (plasma alanine 
aminotransferase level ≥100 IU/L), renal disease (plasma 
creatinine ≥2.2 mg/dL), and hypersensitivity to contrast dye. 
The study subjects were divided into ACS, SA, and con-
trol groups. In this study, the non-ACS group included both 
the control and SA groups. The control group was com-
posed of patients who did not have significant coronary ar-
tery stenosis despite chest pain‒likely atypical pattern. SA 
was defined as no changes in angina symptoms in the pre-
ceding 6 weeks, with no biomarkers of necrosis. Patients 
who underwent follow-up coronary angiography 9‒12 
months after the previous procedure, due either to residual 
stenotic lesions or to a history of stenting, were also includ-
ed in the SA group. In contrast, ACS was characterized by 
typical chest pain, generally occurring at rest or with mini-
mal exertion. The subtypes of ACS included UA and AMI. 
We defined UA as the presence of 1) angina at rest, 2) new 
onset accelerated angina within the past two months, or 3) 
chronic stable angina in patients who developed accelerated 
angina but had not experienced angina at rest during the pre-
ceding two months (according to the Braunwald classifica-
tion).13 Subjects with elevated cardiac biomarkers [e.g., tro-
ponins, creatine kinase (CK), and CK-MB] were categorized 
as AMI patients, and the remaining patients were regarded as 
UA patients.14,15 In addition, we defined heart failure as the 
presence of New York Heart Association (NYHA) class II‒
IV symptoms accompanying cardiomegaly with pulmonary 
congestion on chest X-ray, decreased left ventricular (LV) 
systolic function (EF <50%), LV diastolic dysfunction sug-
gestive of increased LV filling pressure, or cardiogenic shock. 
We defined metabolic syndrome using the National Choles-
terol Education Program‒Third Adult Treatment Panel 
(NCEP ATP III) criteria. The definition of central obesity was 
modified to a body mass index ≥25 kg/m2 because waist cir-
cumference was not measured in most patients. Other criteria 
included high blood pressure (≥130/85 mm Hg or taking an-
acute coronary syndrome (ACS), such as myocardial in-
farction, which may cause sudden death. Progression to 
ACS seems to depend most on exaggerated inflammatory 
changes within atherosclerotic plaques.1-3 
In recent studies, lipoprotein-associated phospholipase A2 
(Lp-PLA2) was found to play a crucial role in the incidence 
of CHD in people whose low-density lipoprotein (LDL) 
concentrations were not predictive of high CHD risk.4 Ear-
lier reports suggested a relation between Lp-PLA2 and CHD 
risk;4-7 however, recent studies have shown that Lp-PLA2 is 
an independent predictor of CHD.5,8 As a biomarker for 
coronary artery disease (CAD), Lp-PLA2 levels are notably 
increased in ACS in particular, because Lp-PLA2 activity is 
associated with vulnerable atherosclerotic plaques.8 Liu, et 
al.9 demonstrated that Lp-PLA2 level is associated with vul-
nerable coronary atherosclerotic plaques and that Lp-PLA2 
could be a strong predictive biomarker for ACS10 In addi-
tion, recent studies have shown that Lp-PLA2 levels are ele-
vated in ACS, which suggests that Lp-PLA2 may be a clini-
cal biomarker for ACS. The clinical diagnostic value of Lp-
PLA2 for ACS; however, has yet to be fully evaluated in 
comparison with other biomarkers, such as high-sensitivity 
C-reactive protein (hs-CRP) or lipoprotein concentration. 
hs-CRP is an accepted biomarker of inflammation and can 
be used as a potential biomarker of plaque instability; nev-
ertheless, a question of tissue specificity has arisen for hs-
CRP. Specifically, it is unclear as to whether hs-CRP is a 
plaque-specific inflammatory marker or a systemic inflam-
matory marker. Lp-PLA2 is specific for vascular inflamma-
tion because it is made by macrophages in the plaque, in 
contrast to other markers of inflammation like CRP, which 
are made in the liver. Lp-PLA2 may hold the potential to be 
a useful, vascular tissue-specific biomarker, if its measure-
ment could be standardized.11,12 Therefore, this study was 
conducted to evaluate the diagnostic value of Lp-PLA2 as 
an independent biomarker of ACS by comparing it to hs-
CRP, which is widely used as a pro-inflammatory marker 
for coronary plaques. 
MATERIALS AND METHODS
Subjects & clinical analysis
We studied 226 consecutive patients scheduled to undergo 
coronary angiography at Gangnam Severance Hospital in 
Seoul, Korea, from 2010 to 2012. Demographic data and 
clinical history were obtained for each patient through chart 
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risk factors, including male gender, age, hypertension, and 
smoking, which were identified as meaningful diagnostic 
tools of ACS in our study using multivariate logistic regres-
sion analysis; 2) Model II: traditional risk factors+elevated 
CRP; and 3) Model III: traditional risk factors+elevated 
CRP+elevated Lp-PLA2 level. Receiver operating charac-
teristic (ROC) analysis was performed to identify the opti-
mal cut-off values for Lp-PLA2 level and hs-CRP level for 
diagnosis of ACS. We also constructed an ROC curve for 
the combination of hs-CRP and Lp-PLA2 levels to evaluate 
whether it showed an improved ability to diagnose ACS. 
Additionally, we used new statistical analysis methods, cal-
culation of integrated discrimination improvement (IDI) 
and net reclassification improvement (NRI) indices, to in-
crease the discriminative value of the new biomarker, Lp-
PLA2 levels. The NRI index is calculated from the net of 
differences between the “upward” movement in categories 
for event subjects and the “downward” movement in those 
for non-event subjects. The IDI index is the difference in 
Yates discrimination slopes between the new and old mod-
els.18,19 Analyses were performed using the statistical soft-
ware SPSS version 18.0 for Windows (IBM Canada Ltd., 
Markham, Ontario, Canada) and SAS version 9.2 (SAS In-
stitute Inc., Cary, NC, USA). Statistical significance was as-





The baseline characteristics and selected laboratory values 
of the study patients are presented in Table 1. There were 
significant differences among the three groups in age, histo-
ry of hypertension, smoking, metabolic scores, heart fail-
ure, statin users (%), and serum HDL cholesterol levels. 
Mean Lp-PLA2 mass level was 15.96±10.88 IU/mL.
Association with acute coronary syndrome
The level of Lp-PLA2 was significantly greater in the ACS 
group than in the SA group (18.00±12.22 IU/mL vs. 13.75± 
7.68 IU/mL, p=0.040). Lp-PLA2 level was also higher in 
the ACS group than in the control group, but this difference 
was not statistically significant (18.00±12.22 IU/mL vs. 
14.21±10.07 IU/mL, p=0.087) (Fig. 1A). Within the ACS 
group, Lp-PLA2 levels tended to be higher in the AMI group 
(19.86±14.19 IU/mL in the AMI group vs. 16.27±9.85 IU/
mL in the UA group, p=0.090) (Fig. 1B). Lp-PLA2 level was 
tihypertensive medication), hyperglycemia (≥110 mg/dL or 
being on hypoglycemic medication or insulin therapy), hy-
pertriglyceridemia (≥150 mg/dL or taking a lipid-lowering 
agent), and low high-density lipoprotein (HDL) cholesterol 
(<40 mg/dL in men, <50 mg/dL in women or taking a lipid-
lowering agent). We classified patients as having metabolic 
syndrome when they met three or more of these five criteria. 
Biochemical tests 
For measurement of Lp-PLA2 concentration in plasma, 5 mL 
of fasting blood samples were drawn before coronary angi-
ography was performed. The blood samples, collected in 
EDTA, were centrifuged at 1000×g for 15 minutes at -20°C 
within 30 minutes of collection, and the separated samples 
were stored at -80°C. Plasma concentrations of Lp-PLA2, 
which was the mass level of Lp-PLA2, was determined using 
a commercially available Lp-PLA2 enzyme-linked immuno-
sorbent assay (ELISA) kit (CUSABIO Biotech, Wuhan, Chi-
na), an ELISA test with two specific monoclonal antibod-
ies.16,17 Each sample was measured twice and the mean of the 
two values was calculated to minimize error. The interassay 
coefficient of variation was 16.11%. hs-CRP levels were 
measured using the latex-enhanced immunoturbidimetric 
method (Denka Seiken Co., Ltd., Tokyo, Japan) with a de-
tection limit of 0.09 mg/L in serum, using a Hitachi 7600-
110 automatic analyzer (Hitachi Co., Tokyo, Japan). Total 
cholesterol, LDL cholesterol, HDL cholesterol, and triglyc-
eride levels in serum were measured using the standard en-
zymatic method (Daiichi Sankyo Co., Ltd., Tokyo, Japan for 
total, LDL and HDL cholesterol; Roche Diagnostics, India-
napolis, IN, USA for triglycerides) with a Hitachi 7600-110 
analyzer (Hitachi Co., Tokyo, Japan).
Statistical analyses
Data are presented as a percentage or mean value±standard 
error. Two group comparisons were made using the Stu-
dent’s t-test for continuous variables or the χ2 test for cate-
gorical variables. Multiple group comparisons were per-
formed by analysis of variance, followed by Tukey-Kramer 
post-hoc analysis. To assess the relation between Lp-PLA2 
and serum hs-CRP levels, we conducted bivariate correla-
tion analysis. Univariate and multivariate logistic regres-
sion analyses were performed to identify the risk factors for 
ACS. In addition, univariate and multivariate Cox regres-
sion analyses were used to identify diagnostic tools of ACS. 
To identify the incremental value of Lp-PLA2 in diagnosis 
of ACS, three models were designed: 1) Model I: traditional 
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old age, Lp-PLA2 level, hs-CRP level, smoking, and heart 
failure were significantly associated with ACS (Table 2). 
Multivariate logistic regression analysis showed that old 
age and Lp-PLA2 level were significantly associated with 
ACS. Lp-PLA2 level was associated with the prevalence of 
ACS with an odds ratio (OR) of 1.047 [95% confidence in-
terval (CI): 1.010‒1.086, p=0.013], and this association was 
statistically significant (Table 2). 
To evaluate the incremental value of Lp-PLA2 as a bio-
marker for diagnosis of ACS over traditional risk factors 
and CRP, we measured global χ2 values. Significant in-
creases in global χ2 values were observed with elevated hs-
CRP level over traditional risk factors (male sex, age, hy-
insignificantly higher in the UA group than in the SA group 
(16.27±9.85 IU/mL in the UA group vs. 13.75±7.68 IU/mL 
in the SA group, p=0.124). In addition, serum hs-CRP con-
centration was significantly higher in the ACS group than in 
the control group (7.57±18.03 IU/mL vs. 1.86±3.20 IU/mL, 
p=0.044) and higher in the ACS group than in the SA group, 
but this latter difference was not statistically significant 
(7.57±18.03 IU/mL vs. 2.73±5.54 IU/mL, p=0.087) (Fig. 
1A). The relation between Lp-PLA2 and hs-CRP levels was 
not statistically significant either within the group of ACS 
patients (r=0.056, p=0.607) or within the population of pa-
tients as a whole (r=0.065, p=0.387). 
Using univariate logistic regression analysis, male sex, 
Table 1. Baseline Characteristics 
Characteristics Control (n=53) SA (n=57) ACS (n=116) p value
Age, yrs 58.04±7.83 63.51±8.48   64.32±11.98 0.001
Male, n (%) 27 (50.9) 32 (56.1) 80 (69.0) 0.052
Hypertension, n (%) 32 (60.4) 47 (82.5) 68 (58.6) 0.006
Diabetes mellitus n (%)   9 (17.0) 18 (31.6) 39 (33.6) 0.079
Dyslipidemia, n (%)   0 (37.7) 32 (56.1) 46 (39.7) 0.077
    Tot. cholesterol, mg/dL 178.20±32.18 162.11±38.44 168.40±42.73 0.109
    TG, mg/dL 134.35±91.11 137.48±88.30 122.05±90.73 0.534
    HDL, mg/dL   48.04±11.32   43.60±13.28   41.49±10.35 0.004
    LDL, mg/dL 108.41±32.11   94.84±33.25 100.60±32.02 0.147
Smoking, n (%) 18 (34.0) 25 (43.9) 63 (54.3) 0.042
Metabolic syndrome, n (%) 26 (49.1) 37 (64.9) 72 (62.1) 0.182
    Metabolic score   2.44±1.43   3.11±1.31   2.97±1.29 0.044
Heart failure, n (%) 3 (5.7) 5 (8.8) 35 (30.2) 0.000
Statin user, n (%) 16 (30.2) 30 (52.6) 42 (36.2) 0.038
Lp-PLA2, IU/mL   14.21±10.07 13.75±7.68   18.00±12.22 0.020
SA, stable angina; ACS, acute coronary syndrome; Lp-PLA2, lipoprotein-associated phospholipase A2.
Fig. 1. Lp-PLA2 and hs-CRP levels in each group. (A) Levels of Lp-PLA2 and CRP in control, SA, and ACS groups. In Lp-PLA2, p=0.040, compared with SA 
group. In CRP, p=0.044, compared with control group. (B) Levels of Lp-PLA2 and CRP in ACS group including UA and AMI groups. Lp-PLA2, lipoprotein-associ-
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though the differences were not statistically significant, Lp-
PLA2 levels tended to be lower in statin users than in statin 
non-users in each group (14.19±12.70 vs. 14.21±8.91, 
12.43±6.87 vs. 15.22±8.38, and 15.78±10.22 vs. 19.26± 
13.12 IU/mL in the control, SA, and ACS groups, respec-
tively) (p=0.996, 0.178, 0.116, respectively).
DISCUSSION
The main pathophysiological mechanism of ACS is erosion 
and rupture of the atherosclerotic plaque, which results in 
pertension, and smoking) for diagnosis of ACS (Model I 
vs. Model II: 18.413 vs. 28.14, incremental global χ2 value: 
9.727, p=0.002) and with elevated Lp-PLA2 level over tra-
ditional risk factors and elevated hs-CRP level (Model II 
vs. Model III: 28.14 vs. 35.602, incremental global χ2 val-
ue: 7.462, p=0.006) (Fig. 2).
To determine the sensitivity and specificity of Lp-PLA2 
levels for diagnosis of ACS, we performed ROC analysis. 
The area under the ROC curve (AUC) of Lp-PLA2 levels 
for ACS was 0.624 (95% CI: 0.542‒0.706, p=0.004). ROC 
analysis showed that the optimal cut-off value for Lp-PLA2 
level was 15.41 IU/mL, and the sensitivity and specificity 
for diagnosis of ACS were 51.8% and 74%, respectively. 
We also evaluated the optimal cut-off value of hs-CRP lev-
els: the AUC for ACS was 0.673 (95% CI: 0.594‒0.752, 
p=0.000), the optimal cut-off value of hs-CRP was 1.85 IU/
mL, and the sensitivity and specificity for diagnosis of ACS 
were 57.6% and 70.8%, respectively (Fig. 3). As compared 
with hs-CRP level, combination of Lp-PLA2 with serum hs-
CRP levels tended to increase the AUC (0.695, 95% CI: 
0.618‒0.772, p=0.017) for diagnosis of ACS (Fig. 3). How-
ever, when using new statistical analysis methods (NRI and 
IDI indices), we found that the addition of Lp-PLA2 level to 
hs-CRP level improved the ability to diagnose ACS. The ad-
dition of Lp-PLA2 level to hs-CRP level yielded an IDI of 
0.0368% (p=0.0093, SE: 0.0142) and an NRI of 0.0854% 
(p=0.2046, SE: 0.0673). 
 
Effect of statins (statin users vs. statin non-users)
We analyzed the levels of Lp-PLA2 according to statin use at 
the time of coronary angiography. The study patients were 
treated with atorvastatin, simvastatin, or rosuvastatin. Al-




OR 95% CI p value OR 95% CI p value
Age 1.033 1.007‒1.060 0.014 1.050 1.013‒1.089 0.008
Male gender 1.897 1.101‒3.268 0.021 1.759 0.652‒0.746 0.265
Hypertension 0.548 0.314‒0.956 0.034 0.519 0.244‒1.105 0.089
Diabetes mellitus 1.577 0.882‒2.820 0.124
LDL-cholesterol 0.999 0.991‒1.007 0.843
Lp-PLA2 1.039 1.011‒1.068 0.007 1.047 1.010‒1.086 0.013
CRP 1.080 1.014‒1.151 0.017 1.065 0.998‒1.135 0.057
Smoking 1.823 1.073‒3.097 0.026 1.420 0.569‒3.546 0.453
Metabolic syndrome 1.204 0.706‒2.051 0.495
Heart failure 5.578   2.452‒12.690 0.000 3.046 1.116‒8.311 0.030
Statin nonuser 0.800 0.468‒1.369 0.416
ACS, acute coronary syndrome; CI, confidence interval; CRP, C-reactive protein.
Fig. 2. Bar chart comparing global χ2 values with three models for diagnosis 
of ACS. CRP had incremental value over traditional risk factors (Model I vs. 
Model II: 18.413 vs. 28.14, incremental global χ2 value: 9.727, p=0.002), and 
Lp-PLA2 level had incremental value over traditional risk factors and CRP 
(Model II vs. Model III: 28.14 vs. 35.602, incremental global χ2 value: 7.462, 
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myocardial hypoperfusion.20 Lp-PLA2 is an enzyme found 
in atherosclerotic plaques, and it exists in the bloodstream 
bound to LDL.11,21,22 Numerous studies have shown that 
ruptured plaques contain more immune and inflammatory 
effector cells than do intact plaques and that Lp-PLA2 may 
be an essential factor in the association between lipopro-
teins and inflammation.23 Lp-PLA2 is abundantly expressed 
within the atherosclerotic plaques,9,24,25 and its enzymatic 
products take part in the progression of inflammation and cell 
death, rendering the plaque vulnerable to rupture.23,26 There-
fore, the amount of plasma Lp-PLA2 reflects the plaque bur-
den and inflammatory activity of atherosclerosis and en-
ables the prediction of cardiovascular outcomes in patients 
with CHD. Herein, we measured plasma Lp-PLA2 mass 
levels, which have been shown to have a strong positive 
correlation with plasma Lp-PLA2 activity.16,27 Plasma Lp-
PLA2 activity is related to plaque rupture, and it may be a 
marker for vulnerable plaques.28 In this study, we investi-
gated the possible role of Lp-PLA2 levels as a diagnostic 
biomarker for ACS with vulnerable plaques. Our analysis 
of 226 participants showed that Lp-PLA2 levels are associ-
ated with risk of ACS. We found that Lp-PLA2 levels were 
significantly increased in the ACS group, and within this 
group, Lp-PLA2 levels were greater in the AMI group than 
in the UA group. This finding may be a result of the relation 
between vulnerable plaque rupture and Lp-PLA2 level.14 To 
exclude the effect of the myocardial injury, we compared 
Lp-PLA2 levels between the SA group and UA group, omit-
ting the AMI group. Lp-PLA2 levels tended to be higher in 
the UA group than in the SA group, which suggest Lp-PLA2 
is associated with plaque vulnerability, regardless of myo-
cardial injury. There was no significant difference in Lp-
PLA2 levels between the ACS group and the control group, 
which might have resulted from the small number of en-
rolled patients. 
Achieving target LDL cholesterol concentrations accord-
ing to personal cardiovascular disease risk, based on the 
Framingham risk criteria, is very important for the preven-
tion of primary and secondary atherosclerotic vascular dis-
eases, including CHD. For those with moderate risk, a target 
LDL cholesterol concentration of <130 mg/dL is recom-
mended, based on the Framingham risk calculator. The ATP 
III 2004 guidelines, however, recommend measurement of 
pro-inflammatory biomarkers, specifically Lp-PLA2, as an 
adjustment to classical risk factor assessment. For those pa-
tients classified as having moderate risk, Lp-PLA2 should 
be measured to allow for reclassification and to identify 
Fig. 3. Receiver operating characteristic (ROC) curves. ROC curve for Lp-
PLA2. (A) Area under the ROC curve for Lp-PLA2 was 0.624 [95% confidence 
interval (CI): 0.542--0.706, p=0.004]. ROC curve for hs-CRP. (B) Area under the 
ROC curve for hs-CRP was 0.673 (95% CI: 0.594--0.752, p=0.000). (C) ROC 
curves for Lp-PLA2 (green line), hs-CRP (red line), and Lp-PLA2+hs-CRP 
(blue line). Area under the ROC curve for Lp-PLA2+hs-CRP was 0.695 (95% 
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Lp-PLA2 inhibitors, such as darapladib, have been devel-
oped.8,34 Darapladib was suggested that it might produce sus-
tained inhibition of circulating Lp-PLA2 activity in dyslipid-
emic patients, and be associated with reduction in plaque 
burden in CHD.8,35,36 Darapladib has undergone evaluation 
in the coronary atherosclerosis imaging trial, in which it 
prevented necrotic core expansion, a crucial determinant of 
plaque vulnerability.8 Now, phase III clinical trials, investi-
gating the effects of darapladib on cardiovascular outcome 
in CHD, are ongoing.37-39 In our study, as mentioned above, 
although the finding was not statistically significant, Lp-
PLA2 level tended to be lower in statin users than in statin 
non-users in each of the groups. Among ACS patients, there 
were patients with low Lp-PLA2 levels who had taken 
statins previously. The previous statin users had taken nor-
mal doses of various statins, and Lp-PLA2 levels were mea-
sured only at the time of coronary angiography in this study. 
Therefore, we could not measure Lp-PLA2 after ACS, but 
we could guess that statin usage would reduce Lp-PLA2 lev-
els, as garnered from simultaneous comparisons between 
statin users and non-users in each group. Because some peo-
ple take statins for primary prevention, assessing ACS risk 
solely on the basis of Lp-PLA2 would not be appropriate. In-
deed, patient usage of various medications that may inter-
fere with cholesterol production should also be considered.
The limitations of this study merit consideration. First, be-
cause this was not a prospective study, we could not compare 
sequential measurements of Lp-PLA2 level in the same pa-
tient. Furthermore, there may be differences in baseline Lp-
PLA2 levels among individuals. Therefore, we cannot be 
sure that statins reduce Lp-PLA2 levels. In addition, Lp-
PLA2 levels were slightly greater in the control group. Such 
an unexpected result might be attributable to the small num-
ber of enrolled patients in this study. Also, although coro-
nary angiography is one of the most commonly performed 
procedures for illustrating luminal narrowing and arterial 
anatomy and is considered the gold standard, it only offers 
information about the vessel lumen and does not provide in-
formation on plaque components or on plaque burden with-
in the vessel wall.40 Additionally, coronary angiography was 
performed because the patients in the control group might 
have had chest pain or a positive treadmill test. Therefore, 
microvascular angina or syndrome X is a possible diagno-
sis for those patients, even though their coronary arteries did 
not have significant narrowed lesions. Finally, it is known 
that myocardial damage or death induces inflammatory 
cells from the bone marrow, which could also affect Lp-
those patients in relatively high-risk groups.29 
CRP is a representative risk factor for atherosclerotic in-
flammation, and its concentrations are known to be signifi-
cantly greater in patients with ACS than in those without 
ACS.30,31 Similarly, because the concentration of Lp-PLA2 
is greater in patients with ACS, Lp-PLA2 may be a good 
biomarker for diagnosis of ACS, as is CRP. In this study, 
we used more sensitive tests to evaluate improvement in 
model performance and usefulness of the new biomarker.18 
We evaluated the ability of Lp-PLA2 in combination with 
CRP to diagnose ACS by calculation of net reclassification 
improvement and integrated discrimination improvement 
indices. Although the diagnostic power was lower, as com-
pared with serum hs-CRP concentration, the addition of Lp-
PLA2 level to serum hs-CRP concentration could signifi-
cantly improve the ability to diagnose ACS, as shown by 
IDI indices. 
Traditional risk factors such as LDL cholesterol or HDL 
cholesterol cannot be used to directly assess plaque-rupturing 
tendency, but greater amounts of Lp-PLA2 signify plaque in-
stability. Interventions to decrease Lp-PLA2 activity, such 
as statin administration, might be useful for stabilizing vul-
nerable plaques in patients with ACS; thus, intensified lip-
id-lowering therapy might be emphasized. Lp-PLA2 level 
tended to be lower in statin users than in statin non-users in 
each group in our study, although this result was not statisti-
cally significant. Patients with hypercholesterolemia have 
elevated levels of oxidized LDL (OxLDL) in the plasma. 
OxLDL can induce the expression of the procoagulant pro-
tein tissue factor (TF) in human monocytes and can also ac-
tivate the coagulation system. Statins reduce the levels of 
OxLDL and thus inhibit inducible TF expression in the aor-
ta and in atherosclerotic lesions.32 Reduced OxLDL levels 
and reduced TF expression lead to the inactivation of the 
coagulation system and should inhibit the development of a 
prothrombotic state. Therefore, statins can reduce inflamma-
tion and thrombogenicity in patients with hypercholesterol-
emia, and it is suggested that statins may lower the risk of ad-
vanced cardiovascular disease, including ACS. Indeed, more 
evidence of a statin effect was shown in the Myocardial Isch-
emia Reduction with Aggressive Cholesterol Lowering 
(MIRACL) trial. A substudy with analysis of the MIRACL 
trial cohort revealed that high-dose atorvastatin significant-
ly decreases Lp-PLA2 mass and activity after ACS.33 Cur-
rently, Lp-PLA2 inhibition is thought to lead to reduced 
phospholipid oxidation and reduced expression of adhesion 
molecules that accelerate atherogenesis. Therefore, specific 
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cular Angiography and Interventions, and the Society of Thoracic 
Surgeons: endorsed by the American Association of Cardiovascu-
lar and Pulmonary Rehabilitation and the Society for Academic 
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2008;27:157-72.
19. Cook NR, Ridker PM. Advances in measuring the effect of indi-
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et al. ESC Guidelines for the management of acute coronary syn-
dromes in patients presenting without persistent ST-segment ele-
vation: The Task Force for the management of acute coronary 
syndromes (ACS) in patients presenting without persistent ST-
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PLA2 level. To discriminate which factor was related to in-
creased Lp-PLA2 levels, identification of tissue characteris-
tics, such as by MRI, might be needed.
In conclusion, Lp-PLA2 may be of use as a meaningful 
biomarker to diagnose ACS independent of hs-CRP and lipid 
profiles. Although Lp-PLA2 measurement is not widely used 
in the clinic, use of this biomarker could help tailor an indi-
vidualized treatment approach to patients with ACS. Specifi-
cally, patients with higher levels of Lp-PLA2 at baseline 
could appear to have an increased risk of cardiovascular 
events. Thus, we could select, at an early stage, patients with 
high levels of Lp-PLA2 who might benefit from aggressive 
lifestyle modification and more robust risk reduction strate-
gies, such as intensified lipid-lowering therapy, with the 
overall effect of reducing the morbidity and mortality of car-
diovascular disease. 
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